LTA type | Lung | Cardiac | Nerve | Skin | ||||
p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | |
Univariate analysis | ||||||||
Pranlukast | 0.14 | 0.2 (0.02 to 1.8)* | 0.006 | 0.15 (0.03 to 0.6)* | 0.09 | 2.9 (0.8 to 10.6)* | 0.71 | 0.8 (0.2 to 2.6)* |
Zafirlukast | 0.15 | 1.9 (0.5 to 7.1)* | 0.32 | 3.1 (0.3 to 29.3)* | 0.71 | 0.001 (0 to 1×1017)* | 0.28 | 2.1 (0.5 to 8.1)* |
Montelukast | 0.35 | 1.0 | 0.003 | 1.0 | 0.23 | 1.0 | 0.41 | 1.0 |
Multivariate analysis | ||||||||
Pranlukast | 0.43 | 0.5 (0.1 to 3.2)* | 0.01 | 0.1 (0.03 to 0.7)* | 0.05 | 5.6 (0.97 to 32)* | 0.1 | 0.9 (0.2 to 3.5) |
Zafirlukast | 0.09 | 8.3 (0.8 to 59)* | 0.6 | 2.0 (0.2 to 24)* | 0.8 | 0.6 (0.01 to 246)* | 0.9 | 5.6 (0.8 to 40) |
Montelukast | 0.11 | 1.0 | 0.03 | 1.0 | 0.15 | 1.0 | 0.2 | 1.0 |
We performed univariate and multivariate logistic regression examining predictors of the pattern of organ expression (dependent variable), the latter controlling for antineutrophil cytoplasmic antibody status and patient group.
*Compared with montelukast. LTA, leukotriene antagonist.